EVQLV Welcomes Chief Scientific Officer Richard Fox

Nov 9, 2020 | News | 0 comments

EVQLV

NEW YORK, November 9, 2020 — EVQLV’s founders are thrilled to (officially) announce that Richard Fox has joined our team as Chief Scientific Officer. Dr. Fox spent nearly two decades at the Fred Hutchinson Cancer Research Center. Within industry he led virology efforts for the HIV, Hepatitis C and coinfection franchises at Merck that included the commercial launch of Zepatier.  Prior to embarking on his scientific career Dr. Fox had a distinguished career in the U.S. Special Forces. Richard is guiding the scientific strategy of the company and ensuring that the experiments we run to validate our technology are scientifically valuable, clinically relevant, and bring us to the clinic.

0 Comments

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...

Fully Automated Rabbit Humanization Project Initiated w/ U Buffalo

NEW YORK, December 16, 2020 -- EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated...

EVQLV Accepted to Prestigious Techstars Boston Accelerator

NEW YORK, November 18, 2020 -- EVQLV, a New York company that uses AI to accelerate the development of antibodies, will be one of 10 startups in the new class of the Techstars Boston program. This year’s program will be 100% virtual and, for the first time, will...

Pin It on Pinterest